HK Web3 Feastival Panel: From "Asset Filing" to "On-Chain Issuance", Bridging the Last Mile for RWA Cross-Border Compliance
ChainCatcher live report: Tang Bo, Associate Dean of the Institute of Finance at the Hong Kong University of Science and Technology, Fei Si, Partner at King & Wood Mallesons, Diao Zhihai, Head of International Wealth Management at China International Capital Corporation, and Gavin Wang, Managing Partner and Chief Investment Officer of SNZ Holding & SNZ Capital, jointly attended the HK Web3 Feastival roundtable to share insights on “from asset registration to on-chain issuance,” facilitating the last mile of cross-border RWA compliance.
Fei Si pointed out that “from asset registration to on-chain issuance” essentially means creating a replicable, sustainable, and legally compliant channel for “domestic assets, overseas issuance.” He believes the most critical step at this stage is to first design the transaction structure and product at the top level, clarifying whether the product falls under equity or debt categories, as this directly determines the corresponding regulatory authorities, communication methods, and subsequent legal documentation arrangements.
From the perspective of practical operations at traditional financial institutions, Diao Zhihai believes that the biggest challenge is not a single pain point, but rather how to systematically connect multiple compliance nodes to form a truly workable closed-loop mechanism. He stated that cross-border RWA projects involve not only financial regulation, but also require collaboration across data transfers, cybersecurity, and foreign exchange management, so it is essential from the outset to examine whether the underlying assets can be clearly defined and mapped on-chain, who qualifies as a legitimate issuer and controlling entity, and whether all non-financial regulatory requirements throughout the whole process have been considered in the solution.
Gavin Wang, from the angle of investment and market demand, emphasized that global asset tokenization is already an inevitable trend, and high-quality Chinese assets are still evidently undervalued overseas, which means that as soon as cross-border compliance channels are established, real market demand will emerge. He believes that investment institutions care most about whether a project has clearly defined compliance boundaries and is marketable: clear regulatory lines must not be crossed, caution must be exercised around grey areas, and the most worthwhile investments are those assets with clearer regulatory outlooks that investors can more easily understand and accept. In the long run, he is most optimistic about two types of cross-border Chinese RWA: one is large-scale, high-quality Chinese assets that overseas investors can easily understand, and the other is globally competitive industrial assets in areas such as high-end manufacturing, robotics, AI, and pharmaceutical pipelines that remain undervalued abroad.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Offshore oil and gas module equipment company VME (VME.US) aiming for Nasdaq listing, plans to raise up to 30 million USD
Offshore oil and gas process module and separation equipment company VME Companies has applied for an IPO on Nasdaq, aiming to raise up to $30 million, with Kingswood as the sole bookrunner.
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).
Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential
According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.
Autoimmune and inflammatory disease pharmaceutical company TRex Bio (TRX.US) applies for US listing, plans to raise up to 100 millions dollars.
TRex Bio filed documents with the U.S. Securities and Exchange Commission (SEC) last Friday, intending to raise up to 100 million USD through an initial public offering (IPO).
